In addition, sequential passive–active tumor targeting facilitated by large molecular weight PDCs via the EPR effect and the use of GFLG as a selective cathepsin B substrate and mechanism of drug release, respectively, will improve therapeutic efficacy and eliminate non-specific toxicity to healthy cells. Here, CTSB is linked to neoplasm.